Compare iShares MSCI Hong Kong ETF (EWH) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 157.2× iShares MSCI Hong Kong ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Gilead Sciences, Inc. for 111 Days on average.
| EWH | GILD | |
|---|---|---|
Market Cap | $1.16B | $182.40B |
Volume | 3,176,523 | 4,469,821 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $155.80 |
52-Week Low | $20.66 | $117.18 |
Typical Hold Time | 61 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.72 with a slight 0.65% daily gain amid a predominantly bearish technical backdrop. The ETF's underlying index, the Hang Seng, has faced significant pressure, dropping over 11% from yearly highs due to Federal Reserve policy concerns and US-Iran geopolitical tensions. Technical indicators show bearish moving averages but neutral oscillators, with RSI levels suggesting potential oversold conditions. Recent institutional activity includes Empowered Funds reducing its position by 70.2% in August 2026.
The outlook remains challenged by Hong Kong's market volatility and external pressures, though current levels may attract contrarian interest given the substantial decline from peaks. Key risks include ongoing geopolitical friction, Federal Reserve policy impacts, and China's economic struggles. Upside potential depends on stabilization in Chinese technology stocks and resolution of international tensions.
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
